Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies.
作者信息
Einsele Hermann, Briones Javier, Ciceri Fabio, García-Cadenas Irene, Falkenburg Fred, Bolaños Natacha, Heemskerk H M Mirjam, Houot Roch, Hudecek Michael, Locatelli Franco, Morgan Kate, Morris C Emma, O'Dwyer Michael, Gil Jordi Sierra, van den Brink Marcel, van de Loosdrecht Arjan A
机构信息
Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany.
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
出版信息
Hemasphere. 2020 Jun 29;4(4):e423. doi: 10.1097/HS9.0000000000000423. eCollection 2020 Aug.
Abstract
摘要
相似文献
1
Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies.血液系统恶性肿瘤的免疫疗法：欧洲血液学协会血液系统恶性肿瘤免疫治疗特别工作组的最新进展
Hemasphere. 2020 Jun 29;4(4):e423. doi: 10.1097/HS9.0000000000000423. eCollection 2020 Aug.
2
The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies.欧洲血液学协会研究路线图：血液系统恶性肿瘤的免疫治疗
Hemasphere. 2021 Sep 10;5(10):e642. doi: 10.1097/HS9.0000000000000642. eCollection 2021 Oct.
3
Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.血液系统恶性肿瘤的过继性免疫治疗：嵌合抗原受体T细胞的现状与新见解
Blood Cells Mol Dis. 2016 Nov;62:49-63. doi: 10.1016/j.bcmd.2016.11.001. Epub 2016 Nov 10.
4
Immunotherapy of hematological malignancies using dendritic cells.利用树突状细胞对血液系统恶性肿瘤进行免疫治疗。
Bull Cancer. 2008 Mar;95(3):320-6. doi: 10.1684/bdc.2008.0602.
5
Immunotherapy for hematological malignancies.血液系统恶性肿瘤的免疫治疗
J Life Sci (Westlake Village). 2019 Jun;1(1):46-52.
6
Discovery and application of immune biomarkers for hematological malignancies.免疫生物标志物在血液系统恶性肿瘤中的发现和应用。
Expert Rev Mol Diagn. 2017 Nov;17(11):983-1000. doi: 10.1080/14737159.2017.1381560. Epub 2017 Sep 25.
7
Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.程序性死亡-1免疫检查点阻断在血液系统恶性肿瘤治疗中的应用
Ann Med. 2016 Sep;48(6):428-439. doi: 10.1080/07853890.2016.1186827. Epub 2016 May 25.
8
Novel Immunotherapies for Hematological Malignancies.血液系统恶性肿瘤的新型免疫疗法。
Curr Mol Pharmacol. 2016;9(3):264-271. doi: 10.2174/1874467208666150716121253.
9
Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.嵌合抗原受体T细胞疗法治疗B细胞血液系统恶性肿瘤：关键临床试验数据更新
Pharmaceutics. 2020 Feb 24;12(2):194. doi: 10.3390/pharmaceutics12020194.
10
Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy.淫羊藿素：血液系统恶性肿瘤治疗的新型天然候选药物。
Biomed Res Int. 2019 Mar 28;2019:4860268. doi: 10.1155/2019/4860268. eCollection 2019.
引用本文的文献
1
The Evolving Role of Haematology Nursing Practice: A Cross-Sectional Survey.血液学护理实践的演变角色：一项横断面调查。
Mediterr J Hematol Infect Dis. 2023 May 1;15(1):e2023033. doi: 10.4084/MJHID.2023.033. eCollection 2023.
2
Polyphenols: Chemoprevention and therapeutic potentials in hematological malignancies.多酚类物质：血液系统恶性肿瘤中的化学预防及治疗潜力
Front Nutr. 2022 Oct 26;9:1008893. doi: 10.3389/fnut.2022.1008893. eCollection 2022.
3
Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?代谢因素对肿瘤免疫原性的影响：细胞水平上发生了什么？
Int J Mol Sci. 2021 Feb 21;22(4):2142. doi: 10.3390/ijms22042142.
本文引用的文献
1
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.抗 B 细胞成熟抗原双特异性 T 细胞衔接分子 AMG 420 诱导多发性骨髓瘤产生应答。
J Clin Oncol. 2020 Mar 10;38(8):775-783. doi: 10.1200/JCO.19.02657. Epub 2020 Jan 2.
2
Immune Checkpoint Inhibition in Hodgkin Lymphoma.霍奇金淋巴瘤中的免疫检查点抑制
Hemasphere. 2018 Feb 16;2(1):e20. doi: 10.1097/HS9.0000000000000020. eCollection 2018 Jan-Feb.
3
A highly soluble Sleeping Beauty transposase improves control of gene insertion.高度可溶性的“睡美人”转座酶可提高基因插入的控制。
Nat Biotechnol. 2019 Dec;37(12):1502-1512. doi: 10.1038/s41587-019-0291-z. Epub 2019 Nov 4.
4
Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.造血干细胞工程化不变自然杀伤 T 细胞治疗癌症的研究进展。
Cell Stem Cell. 2019 Oct 3;25(4):542-557.e9. doi: 10.1016/j.stem.2019.08.004. Epub 2019 Sep 5.
5
Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation.检查点抑制预防或治疗异基因造血细胞移植后复发。
Bone Marrow Transplant. 2019 Aug;54(Suppl 2):798-802. doi: 10.1038/s41409-019-0617-y.
6
Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function.正交替换 T 细胞受体 α 和 β 链，同时保留近乎生理的 T 细胞功能。
Nat Biomed Eng. 2019 Dec;3(12):974-984. doi: 10.1038/s41551-019-0409-0. Epub 2019 Jun 10.
7
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.抗 BCMA CAR T 细胞疗法 bb2121 治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.
8
Therapeutic gene editing in haematological disorders with CRISPR/Cas9.CRISPR/Cas9 基因编辑治疗血液系统疾病。
Br J Haematol. 2019 Jun;185(5):821-835. doi: 10.1111/bjh.15851. Epub 2019 Mar 12.
9
Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia.监测异基因造血干细胞移植治疗急性髓系白血病中 TIGIT/DNAM-1 和 PVR/PVRL2 免疫检查点表达水平。
Biol Blood Marrow Transplant. 2019 May;25(5):861-867. doi: 10.1016/j.bbmt.2019.01.013. Epub 2019 Jan 11.
10
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.美国霍奇金淋巴瘤患者程序性死亡受体-1（PD-1）抑制剂的疗效和毒性：一项真实世界、多中心回顾性分析。
Oncologist. 2019 Jul;24(7):955-962. doi: 10.1634/theoncologist.2018-0538. Epub 2018 Dec 19.
Zotero 插件